Hyderabad doctor brings down rare disease drug cost by ₹6.5 lakh; seven children to get free treatment
Seven children diagnosed with Allan-Herndon-Dudley syndrome (AHDS), a rare genetic disorder, are set to receive a year’s supply of the medicine tiratricol free of cost on November 30; the compounded formulation is estimated to cost just ₹2.5 lakh per child for a year
The Hyderabad-based pediatrician Dr Sivaranjani Santosh, along with Access to Medicines India, has managed to bring down the cost of a rare disease drug by ₹6.5 lakh, ensuring that seven children with a severe genetic disorder can now receive the treatment they need. These children, diagnosed with Allan-Herndon-Dudley syndrome (AHDS), would have previously had to pay an exorbitant price for the drug, which could cost anywhere between ₹4.68 crore to ₹9 crore per child annually.
The drug, tiratricol or TRIAC, is now being provided to the children for free, thanks to pharmaceutical compounding in the Netherlands. The compounded version costs just ₹2.5 lakh per child for a year, a drastic reduction from its commercial price. This medicine was prepared by Transvaal Pharmacy in The Hague, in collaboration with the Netherlands-based Pharmaceutical Accountability Foundation (PAF).
After Dr Sivaranjani's child, Arav, was diagnosed with AHDS, she began her mission to make the medication accessible to others. Her social media outreach led to the involvement of PAF, which in turn engaged Transvaal Pharmacy to compound the medicine. The initiative has been successful, with the first batch of the compounded medicine set to be delivered to the parents of the seven children on November 30.
However, while this is a triumph for the seven children and their families, Dr Sivaranjani has expressed her hope to see the medicine compounded in India, making it accessible to more children with this rare genetic disorder.
Written by urgent.news from The Hindu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.